Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis
© Johnson et al.; licensee BioMed Central Ltd. 2013
Received: 10 May 2013
Accepted: 29 October 2013
Published: 4 November 2013
Currently, there are no consistently effective chemotherapies for recurrent and inoperable meningiomas. Recently, cucurbitacin I (JSI-124), a naturally occurring tetracyclic triterpenoid compound used as folk medicines has been found to have cytoxic and anti-proliferative properties in several malignancies thru inhibition of activator of transcription (STAT3) activation. Previously, we have found STAT3 to be activated in meningiomas, particularly higher grade tumors.
Primary leptomeningeal cultures were established from 17, 20 and 22 week human fetuses and meningioma cell cultures were established from 6 World Health Organization (WHO) grade I or II meningiomas. Cells were treated with cerebrospinal fluid from patients without neurologic disease. The effects of cucurbitacin I on cerebrospinal fluid stimulation of meningioma cell DNA synthesis phosphorylation/activation of JAK1, STAT3, pMEK1/2, p44/42MAPK, Akt, mTOR, Rb and caspase 3 activation were analyzed in human leptomeningeal and meningioma cells.
Cerebrospinal fluid significantly stimulated DNA synthesis in leptomeningeal cells. Co-administration of cucurbitacin I (250 nM) produces a significant blockade of this effect. Cucurbitacin I alone also produced a significant reduction in basal DNA synthesis. In grade I and II meningiomas, cerebrospinal fluid also significantly stimulated DNA synthesis. Co-administration of cucurbitacin I (250 nM) blocked this effect.
In the leptomeningeal cultures, cerebrospinal fluid stimulated STAT3 phosphorylation but not p44/42MAPK, Akt or mTOR. Cucurbitacin I had no effect on basal STAT3 phosphorylation but co-administration with cerebrospinal fluid blocked cerebrospinal fluid stimulation of STAT3 phosphorylation in each. In the grade I meningiomas, cerebrospinal fluid stimulated phosphorylation of STAT3 and decreased MEK1/2 and cucurbitacin I had no effect on basal STAT3, p44/42MAPK, Akt, JAK1, mTOR, or Rb phosphorylation. In the grade II meningiomas, cerebrospinal fluid stimulated STAT3 phosphorylation in all and reduced phosphorylation of MEK1/2 in all and p44/42MAPK in one. Cucurbitacin I had no effect on basal phosphorylation of STAT3 but reduced phorphorylated p44/42 MAPK in 2 grade II meningioma cells lines.
These studies raise the possibility that cucurbitacin I might have value as an adjunct chemotherapy. Additional studies are warranted to evaluate the effects of cucurbitacin I on meningiomas in vivo.
The lack of effective chemotherapies compromises management of recurrent or inoperable meningiomas [1, 2]. Approximately 12% of intracranial world health organization (WHO) grade I meningiomas recur within 5 years of gross total resection [3, 4]. Intracranial, WHO grade II, tumors may recur with a frequency as high as 29-41% within 5 years after gross total resection [5, 6]. Recurrence rates of skull base meningiomas are even higher [7, 8]. In these cases effective chemotherapies have not been established and recent promising treatments have proven suboptimal [9–12]. In most recurrences, management includes radiotherapy but this may be less effective  than in cases of de novo meningiomas where radiation can produce a 93% control at 5 years and 87% at 15 years . In a recent study of Gamma Knife-treated skull base meningiomas, followed for up to 103 months, 33% exhibited variable regression, 64% were stabilized and 6% showed progression . However, stereotactic radiosurgery produced only a 49% progression free survival in atypical, WHO grade II meningiomas and is ineffective in treatment of anaplastic meningiomas . Moreover in some studies, radiotherapy as an initial treatment was less effective in large meningiomas greater than 5 cm3.
Meningioma growth is regulated by complex interactions between multiple mitogenic/anti-apoptotic signaling pathways . Previously, we have found that several of these pathways such as the MAPK kinase kinase-MAPK kinase-mitogen activated protein kinase (Raf-1-MEK-1-MAPK) pathway, phosphoinositide 3 kinase-protein kinase B/Akt-proline rich-Akt substrate 40-mTOR (PI3K-PKB/Akt-PRAS40-mTOR) pathway and phospholipase C-gamma pathways are activated in WHO grade I meningiomas [18–20]. The janus tyrosine kinase (JAK)-signal transducer and activator of transcription (STAT3) pathway, and/or STAT3 might also be involved [21–24]. These pathways may be activated by autocrine or paracrine growth factor/cytokine stimulation of meningioma cells rather than constitutive activation of growth factor receptors or signal transduction pathways [16, 23]. Autocrine production of many mitogenic cytokines and their presence in the cerebrospinal fluid have been established [16, 17, 23, 25].
Previously we have found that cerebrospinal fluid stimulation of leptomeningeal and meningioma cell proliferation is associated, in part, with activation of STAT3. In search of a STAT3 inhibitor, we tested cucrbitacin I on STAT3 activation in one leptomeningeal and meningioma culture . In the present study, to characterize cucurbitacin I, we evaluated its effects on proliferation and growth regulatory pathways in numerous human leptomeningeal, grade I and II meningioma cell cultures. To mimic the in vivo milieu, we stimulated cells with cerebrospinal fluid from patients found to have no neurological disease and platelet derived growth factor BB (PDGF-BB), a known mitogen for meningioma cells [19, 20, 23].
Human leptomeningeal and meningioma cell cultures
Primary leptomeningeal cultures were established from de-identified postmortem leptomeninges from 17, 20 and 22 week human fetuses with University of Rochester Institutional Review Board approval and postmotrm exception but prior autopsy/surgical maternal consent for use of the tissue. Remnant, excess, discarded tissue/meningioma cells were also collected (mean age 61 years; 4 females) with University of Rochester Institutional Review Board approval and surgical consent for use of tissue. M1-M3 were WHO grade I meningothelial meningiomas from the clivus, sphenoid wing or frontal lobe and all had detectable Merlin protein. M4-M6 included a WHO grade II meningothelial, transitional and microcystic meningioma from the frontal lobe and the 2 analyzed also had detectable Merlin protein. These cells were maintained in DMEM with 10% fetal bovine serum (FBS) which is insufficient for normal glia and endothelial cell survival and proliferation. The cells used were screened for features of leptomeningeal and meningioma cells following procedures described previously including detection of a leptomeningeal marker, epithelial membrane antigen (EMA) . For experiments, only early passage i.e. passage 2 to 5 were used on meningioma cell cultures that showed EMA and variable desmoplakin immunoreactivity by immunocytochemistry and Merlin protein [37, 38]. For immunocytochemical characterization, meningioma cell cultures were plated onto 2 well microscope slides (Nalgene NUNC Int., Rochester, NY) for 1 day in DMEM with 10% FBS then fixed in formalin. Immunocytochemistry was performed using a mouse monoclonal antibody against epithelial membrane antigen (EMA, prediluted) (DAKO, Carpenteria, CA) and anti-desmoplakin (1:200; Abcam Inc., Cambridge MA) using the streptavidin-biotin-horseradish peroxidase method. The presence or loss of Neurofibromatosis-2 gene product Merlin was assessed by western blot (data not shown, 37, 38).
Human cerebrospinal fluid from patients without neurologic disease
Remnant, discarded lumbar cerebrospinal fluid was retrieved from samples collected at the University of Rochester Medical Center (Rochester, NY) and sent to the Dept. of Pathology for analysis between March, 2009 and September, 2012. As discarded remnant tissue, it was exempted by the University of Rochester Institutional review board from patient consent forms beyond standard patient consent forms for tissue use. Samples from patients found to be free of neurological disease that had cytopathology analysis showing no erythrocytes or increased lymphocytes and normal indices were classified as “normal”. In patients who had cerebrospinal fluid collected as part of staging protocol for a peripheral lymphoma, only cerebrospinal fluid from those with no cells by cytology and no neurologic disease were used. Due to limited volume, in some cases multiple samples were combined as pools to achieve some uniformity and enough volume to treat large numbers of cells in T75 flasks. Samples were initially frozen at -17°C then stored at -80°C.
Effects of cucurbitacin I on cerebrospinal fluid stimulation of meningioma cell DNA synthesis
Confluent cells from human 17, 20 and 22 week fetal leptomeninges (L1-L3), 3 WHO grade I (M1 -M3) and 3 WHO grade II (M4- M6) were plated in 96 well plates, serum deprived overnight then treated with serum free DMEM, undiluted cerebrospinal fluid, DMEM and cucurbitacin I (250 nM) or cerebrospinal fluid with cucurbitacin (250 nM, Calbiochem, CA) for 72 hrs. This dose was chosen based on the dose response curves and previous literature using doses as high as 10 uM  or lower [30, 31]. Cells were subsequently analyzed in 6 replicates by CyQUANT Cell Proliferation assay (Invitrogen, Carlsbad, CA). Samples were analyzed with a fluorescence microplate reader with filters appropriate for ~480 nm excitation and ~520 nm emission maxima. Differences between treatment groups were analyzed by unpaired, two-tailed T-tests (In Stat, Sigma, St. Louis).
Dose response effects of cucurbitacin I on cerebrospinal fluid and PDGF-BB stimulation of human leptomeningeal and meningioma cell DNA synthesis
For analysis of effects of various doses of cucurbitacin on cerebrospinal fluid stimulation of a grade I (M1) meningioma were also plated in 96 well plates, serum deprived overnight then treated with serum free DMEM, DMEM with cerebrospinal fluid with or without cucurbitacin I 25, 75 or 250 nM for 72 hrs. Cells were subsequently analyzed in 6 replicates by CyQUANT Cell Proliferation assay (Invitrogen, Carlsbad, CA). Differences between treatment groups were analyzed by unpaired, two-tailed T-tests (In Stat, Sigma, St. Louis).
For analysis of effects on PDGF-BB, cells of 20wk fetal leptomeninges, (L2) were also plated in 96 well plates, serum deprived overnight then treated with serum free DMEM, DMEM with recombinant human PDGF-BB (10 ng/ml, R and D, Minneapolis, MN) with or without cucurbitacin I 50, 100 or 200 nM for 72 hrs. Cells were subsequently analyzed as above.
Effects of cerebrospinal fluid and cucurbitacin I on meningioma cell JAK, STAT3, MEK1/2, p44/42MAPK, Akt, mTOR, and Rb activation
Confluent cells from 17, 20 and 22 week primary fetal leptomeningeal cell cultures (L1-3), 2 WHO grade I (M2 -M 3) and 2 WHO grade II primary meningioma cultures (M 4 and M5) were serum deprived overnight then treated with serum free DMEM, cerebrospinal fluid without or with 250 nM cucurbitacin I. Lysates of the cells were then analyzed by Western blots.
For Western blots, meningioma cells were scrapped in RIPA Lysis Buffer (Upstate Biotechnology) with 1:100 Protease Inhibitor Cocktail (Sigma) then vortexed vigorously and frozen at –85°C. Protein concentrations were quantified using a Bradford assay (BioRad Protein Assay reagent), then 10–35 ug protein from each was loaded on 7.5% acrylamide gel then transferred to 0.45 um nitrocellulose membrane. The membrane was blocked 1 hour in 5% milk in Tris-Cl buffer with Tween 20 then reacted with an affinity purified primary antibody overnight at 4°C. This was followed by horseradish peroxidase conjugated secondary antibody treatment. Detection was achieved with Western Lightening (Perkin Elmer) on Xomat film (Kodak).
Western blots were analyzed with monoclonal antibodies to STAT3, phospho-STAT3 phosphorylated at tyrosine 705, JAK, phospho-JAK1 phosphorylated at tyrosine 1022/1023, phosphso-MEK1/2 phosphorylated at serine 221, MAPK 44/42, phospho-MAPK 44/42 phosphorylated at threonine 180/tyrosine 182, Akt, phospho-Akt phosphorylated at threonine 308, phospho-mTOR phosphorylated at serine 2448, Rb and p-Rb phosphorylated at serine 608 (all from Cell Signaling, Beverly MA). Loading was assessed with an antibody to actin.
Effects of cucurbitacin I on caspase 3 activation in meningiomas
To screen for Caspase 3 activation by ARP cleavage, near confluent cells from cultures of 2 leptomeninges (L1 and L3) and a WHO grade I (M1) primary meningioma culture were treated with serum free DMEM with and without cucurbitacin I (250 nM) or cerebrospinal fluid with or without cucurbitacin (250 nM). Cucurbitacin I’s effects on apoptosis was measured by Caspase 3 activation. Poly (ADP ribose) polymerase 1 (PARP) fragmentation is an indirect, semiquatitative measurement of caspase 3 activation and apoptosis. Cleavage of the 117-kDa PARP into the 85 kDa product was assessed by Western blot with antibody to PARP -1 (Santa Cruz, Biotechnology, Santa Cruz, CA) and blotting procedures detailed above.
Effects of cucurbitacin I on cerebrospinal fluid stimulation of meningioma cell DNA synthesis
Effects of cucurbitacin on PDGF-BB stimulation of human leptomeningeal and meningioma cell DNA synthesis
In L2, cucurbitacin I produced a dose dependent reduction in PDGF-BB stimulated DNA synthesis at 50 nM (p = 0.005) 100 nM (p = 0.01) and 200 nM (p = 0.01) doses (Figure 3a).
Effects of cerebrospinal fluid and cucurbitacin I on meningioma cell JAK, STAT3, MEK1/2, p44/42MAPK, Akt, mTOR, and Rb activation
Effects of cucurbitacin I on caspase 3 activation in meningiomas
Western blots reveal intact native 117 kDa PARP in all of the treatment groups. Cucurbitacin I had no effect on activation of caspase 3 in the L1 and L3 leptomeninges or grade I M1 meningioma cells. Cerebrospinal fluid increased the approximately 78 KDa cleavage product in L3 and M1 (data not shown).
In the present study, curcubitacin I blocked cerebrospinal fluid stimulation of leptomeningeal, WHO grade I and II cell proliferation in each of the primary cell cultures. These findings suggest that cucurbitacin may be useful in treatment of select meningiomas. Cucurbitacin I appears to be a potent inhibitor in meningioma cells and effective at concentrations similar to that effective on nasopharyngeal carcinoma cells  and lower than effective on ALK-positive anaplastic large cell lymphoma cells  and pancreatic carcinoma cells .
In previous studies cucurbitacin selectively inhibited phosphorylation of STAT3 but not ERK 1 or 2 (P44/42 MAPK), JNK-1 or AKT in NIH 3 T3 cells and adenocarcinoma cell lines . Nonetheless, our findings suggest the mechanisms underlying cucurbitacins antiproliferative effects on meningioma cells are more complex. In the leptomeninges and one meningioma, cucrbitacin I’s effects correlated with reduced phosphorylation of STAT3. In one grade II meningioma, co-administration of cerebrospinal fluid and cucurbitacin I appeared to increase STAT3 phosphorylation (M4) but this was in a case showing particularly robust proliferation in response to cerebrospinal fluid which might be harder to block. The meningioma cells also, in some instances, reduced phosphorylation of p44/42MAPK. While p44/42MAPK regulates numerous cellular functions, the findings raise the possibility that it might also participate in cucurbitacin I’s antiproliferative effects in some cells and doses.
Previously we have found that STAT3 phosphorylation/activation was associated with cerebrospinal fluid stimulation of irradiated leptomeningeal cell  and meningioma cell proliferation [22, 23]. It is also important in meningioma progression to a higher grade [21, 40, 41]. Cucurbitacin I’s effect on STAT3 appears to be at the level of STAT3 since it had no effect on upstream components of pathways that activate STAT3 particularly JAK1. Cucurbitacin I appears to reduce the level of tyrosine phosphorylation on STAT3 reducing phospho-STAT3 binding to transcription factors . Nonetheless, cucurbitacin I also reduced levels of p44/42MAPK phosphorylation in the leptomeninges, WHO grade I and II meningiomas. Previously we and others have found p44/42MAPK activation important to meningioma cell proliferation [19, 42]. Cucurbitacin also blocked PDGF-BB stimulation of leptomeningeal cell proliferation. PDGF-BB activates STAT3 in some cells and also p44/42 MAPK in leptomeningeal cells consequently cucurbitacin I’s effects could reflect inhibition of STAT3 alone or with p44/42 MAPK.
STAT3 is one of a family of proteins with a phosphotyrosine and DNA binding domain that acts as a transcription factor [43–47]. Latent STAT3 is activated by a several growth factor/cytokine receptors that phosphorylate JAK1 in receptor complexes or STAT3 independently resulting in latent cytoplasmic STAT dimerization and translocation into the nucleus where it increases transcription factors promoting cell proliferation [43–46]. Of interest, recombinant IL-6 treatment reportedly had no effect or was inhibitory to WHO grade I meningioma cell proliferation in vitro . Moreover, cerebrospinal fluid activation/phosphorylation of STAT3, at least in human leptomeningeal and meningioma cells, appears to be independent of an IL-6 receptor-JAK-STAT3 pathway . Thus STAT3 activation may be via several cytokine/growth factor receptor/kinases  and/or by the MEK-1-MAPK and PI3k-Akt-mTOR pathways [44–47] that we and others have found to be mitogenic to meningioma cells [19, 20, 42].
Cucurbitacin I effects on meningioma cell apoptosis are uncertain. Curcubitacin I had no detectable effect on cleavage of PARP, a marker of caspase 3 activity. Nonetheless, due to the limitations inherent to using primary cultures and limited amounts of cerebrospinal fluid from patients without neurological disease, our analysis was limited in scope and time points analyzed. In another study, in combination with gemcitabine, cucurbitacin increased PARP cleavage in pancreactic carcinoma cells .
Cerebrospinal fluid from multiple different patients stimulated leptomeningeal and meningioma cell proliferation. These findings extend our previous observations that cerebrospinal fluid from a numerous different adults of various ages and both genders has the potential to stimulate leptomeningeal or meningioma cell proliferation under some circumstances in vivo and may participate in the pathogenesis of meningiomas . For example, recently we have found that prior irradiation, a known initiator of meningioma formation, may sensitize leptomeningeal cells to the mitogenic effects of cerebrospinal fluid in some scenarios . These findings underscore the need to clarify the effects of cerebrospinal fluid on meningioma growth and identify chemotherapies that may block any mitogenic effects in vivo.
Cucurbitacin I is a potent inhibitor of meningeal and meningioma cell proliferation that warrants further study as a nonsurgical alternative therapy for meningiomas. While its mechanism of action may be primarily thru inhibition of STAT3 phosphorylation/activation, other mechanisms may contribute to its growth inhibitory effects.
- Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD: Medical therapies for meningiomas. J Neurooncol. 2010, 99: 365-378. 10.1007/s11060-010-0349-8.View ArticlePubMedGoogle Scholar
- Chamberlain MC, Barnholtz-Sloan JS: Medical treatment of recurrent meningiomas. Expert Rev Neurother. 2011, 11: 1425-1432. 10.1586/ern.11.38.View ArticlePubMedGoogle Scholar
- Jaaskelainen J: Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 637 patients. A multivariate analysis. Surg Neurol. 1986, 26: 461-469. 10.1016/0090-3019(86)90259-4.View ArticlePubMedGoogle Scholar
- Stafford SL, Perry A, Suman VJ: Primarily resected meningiomas: outcomes and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc. 1998, 73: 936-942. 10.4065/73.10.936.View ArticlePubMedGoogle Scholar
- Perry A, Stafford SL, Scheithauer BW: Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997, 21: 1455-1465. 10.1097/00000478-199712000-00008.View ArticlePubMedGoogle Scholar
- Aghi MK, Carter BS, Cosgrove GR: Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery. 2009, 64: 56-60. 10.1227/01.NEU.0000330399.55586.63.View ArticlePubMedGoogle Scholar
- Maroon JC, Kennerdell JS, Vidovich DV, Alba A, Sternau L: Recurrent spheno-orbital meningioma. J Neurosurg. 1994, 80: 202-208. 10.3171/jns.1994.80.2.0202.View ArticlePubMedGoogle Scholar
- Johnson MD, Sade B, Milano MT, Lee JH, Toms SA: New prospects for management and treatment of inoperable and recurrent skull base meningioma. J Neuro-Oncol. 2008, 86: 109-122. 10.1007/s11060-007-9434-z.View ArticleGoogle Scholar
- Chamberlain MC: Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2011, 107: 315-321.View ArticlePubMedGoogle Scholar
- Schulz C, Mathieu R, Kunz U, Mauer UM: Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011, E11-Google Scholar
- Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC: Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro-oncology. 2011, 13: 530-535. 10.1093/neuonc/nor044.View ArticlePubMedPubMed CentralGoogle Scholar
- Sioka C, Kyritis AP: Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol. 2009, 92: 1-6. 10.1007/s11060-008-9734-y.View ArticlePubMedGoogle Scholar
- Wojcieszyniski AP, Ohri N, Andrews DW, Evans JJ, Dicker AP, Werner-Wasik M: Reirradiation of recurrent meningioma. J Clin Neurosci. 2012, 19: 1261-1264. 10.1016/j.jocn.2012.01.023.View ArticleGoogle Scholar
- Kondziolka D, Mathiei D, Lundsford LD, Martin JJ, Madhock R, Niranjian A, Flickinger JC: Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008, 62: 53-58. 10.1227/01.NEU.0000311061.72626.0D.View ArticlePubMedGoogle Scholar
- Mair R, Morris K, Scott I, Carroll TA: Radiotherapy for atypical meningiomas. J Neurosurg. 2011, 115: 811-819. 10.3171/2011.5.JNS11112.View ArticlePubMedGoogle Scholar
- Bloch O, Gurvinder K, Jian BJ, Parsa AT, Barani IJ: Stereotactic radiosurgery for benign meningiomas. J Neurooncol. 2012, 107: 13-20. 10.1007/s11060-011-0720-4.View ArticlePubMedGoogle Scholar
- Ragel BT, Jensen RL: Aberrant signaling pathways in meningiomas. J Neurooncol. 2010, 99: 315-324. 10.1007/s11060-010-0381-8.View ArticlePubMedGoogle Scholar
- Johnson MD, Horiba M, Arteaga C: The epidermal growth factor receptor is associated with phospholipase C γ in meningiomas. Human Pathol. 1994, 25: 146-153. 10.1016/0046-8177(94)90270-4.View ArticleGoogle Scholar
- Johnson MD, Woodard A, Kim P, Frexes-Steed M: Evidence for mitogen associated protein kinase activation and transduction of mitogenic signals from platelet derived growth factor in human meningioma cells. J Neurosurg. 2001, 94: 303-310.View ArticleGoogle Scholar
- Johnson MD, Okediji E, Woodard A, Toms SA: Evidence for phosphatidylinositol 3-kinase Akt- p70S6K pathway activation and transduction of mitogenic signals by platelet derived growth factor in human meningioma cells. J Neurosurg. 2002, 97: 668-675. 10.3171/jns.2002.97.3.0668.View ArticlePubMedGoogle Scholar
- Magrassi L, De-Fraja C, Conti L, Butti G, Infuso L, Govoni S: Expression of the JAK and STAT superfamilies in human meningiomas. J Neurosurg. 1999, 91: 440-446. 10.3171/jns.1999.91.3.0440.View ArticlePubMedGoogle Scholar
- Johnson MD, O’Connell M, Vito F, Bakos RS: Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol. 2009, 92: 129-135. 10.1007/s11060-008-9746-7.View ArticlePubMedGoogle Scholar
- Johnson MD, O’Connell M, Facik M, Maurer P, Jahromi B, Pilcher W: Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3. J Neurooncol. 2012, 107: 121-133. 10.1007/s11060-011-0736-9.View ArticlePubMedGoogle Scholar
- Silva CM: Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene. 2004, 23: 8017-8023. 10.1038/sj.onc.1208159.View ArticlePubMedGoogle Scholar
- Johanson CE, Duncan JA, Klinge PM, Brinker T, Stopa EG, Silverberg GD: Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res. 2008, 5: 10-42. 10.1186/1743-8454-5-10.View ArticlePubMedPubMed CentralGoogle Scholar
- Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM: Discovery of JSI-124 (Cucurbitacin I) a selective janus kinase/signal transducer and activator of transcritption 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63: 1270-1279.PubMedGoogle Scholar
- Chen JC: Curcurbitacins and cucurbitane glycosides: structures and biolgical activities. Natl Prod Rep. 2005, 22: 386-399. 10.1039/b418841c.View ArticleGoogle Scholar
- Lee DH, Iwanski GB, Thoennissen NH: Cucurbitacin: ancient compound shedding light on cancer treatment. Sci World J. 2010, 10: 4130-Google Scholar
- Iwanski GB, Lee DH, En-Gal S: Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Brit. J Pharmacol. 2010, 160: 998-1007. 10.1111/j.1476-5381.2010.00741.x.View ArticleGoogle Scholar
- Lui VWY, Yau DMS, Wong EYL, Ng Y-K: Cucurbitacin I elicits anoikis senstitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis. 2009, 30: 2085-2094. 10.1093/carcin/bgp253.View ArticlePubMedGoogle Scholar
- Su Y: JSI-124 (Cucurbitacin I) inhibits glioblastoma multiforme proliferation through G2/M cell cycle arrest and apoptosis augment. Cance Biol Ther. 2008, 7: 1243-1249. 10.4161/cbt.7.8.6263.View ArticleGoogle Scholar
- Shi X, Franko B, Frantz C, Amin HM, Lai R: JSI-124 (cucurbitacin1) inhibits Janus kinase -3 signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK) and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol. 2006, 135: 26-32. 10.1111/j.1365-2141.2006.06259.x.View ArticlePubMedGoogle Scholar
- Hsu HS, Huang PI, Chang YL, TZao C, Chen YW: Cucurbitacin 1 inhibits tumorigenic ability and enhances radiochemosenstivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer. 2011, 17: 2970-85.View ArticleGoogle Scholar
- Recio MC: Anti-inflammatory activity of two curbitacins isolated from Cayaponia tayuya roots. Planta Med. 2004, 70: 414-420.View ArticlePubMedGoogle Scholar
- Rios JL: Effects of triterpenes on the immune system. J Ethnopharmacol. 2010, 128: 1-14. 10.1016/j.jep.2009.12.045.View ArticlePubMedGoogle Scholar
- Johnson MD, O’Connell MJ, Vito F, Pilcher W: Bone morphogenetic protein 4 and its receptors are expressed in the leptomeninges and meningiomas and signal via the Smad pathway. J Neuropathol Exp Neurol. 2009, 68: 1177-1183. 10.1097/NEN.0b013e3181bc6642.View ArticlePubMedGoogle Scholar
- Buccoliero AM, Castiglione F, Degl’Innocenti DR, Gheri CF, Garbini F, Taddei A: NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-PCR study. Neuropathology. 2007, 27: 36-42. 10.1111/j.1440-1789.2006.00737.x.View ArticlePubMedGoogle Scholar
- Gusella JF, Ramesh V, MacCollin M: Merlin: the neurofibromatosis 2 tumor suppressor. Biochem Biophys Acta. 1999, 1423: M29-M36.PubMedGoogle Scholar
- Johnson MD, O’Connell M, Anwar Iqbal A, Williams JP: Radiation effects on human leptomeningeal cell response to cerebrospinal fluid and PDGF-BB. Int J Rad Biol. 2012, 88: 145-157.View ArticleGoogle Scholar
- Zhang MX, Zhao X, Wang ZG, Zhao WM, Wang YS: Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation. J Cancer Res Clin Oncol. 2010, 136: 981-988. 10.1007/s00432-009-0743-9.View ArticlePubMedPubMed CentralGoogle Scholar
- Pham MH, Zada G, Mosich GM, Chen TC, Giannotta SL: Molecular genetics of meningiomas; a systematic review of current literature and potential basis for future treatment paradigms. Neurosurg Focus. 2011, 30: E7-View ArticlePubMedGoogle Scholar
- Mawrin C, Sasse T, Kirches E: Different activation of mitogen activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res. 2005, 11: 4074-4082. 10.1158/1078-0432.CCR-04-2550.View ArticlePubMedGoogle Scholar
- Germain D, Frank DA: Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007, 13: 5665-5669. 10.1158/1078-0432.CCR-06-2491.View ArticlePubMedGoogle Scholar
- Klampfer L: Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drugs and Targets. 2006, 6: 107-121. 10.2174/156800906776056491.View ArticleGoogle Scholar
- Kortylewski M, Hua Y: STAT3 as a potential target for cancer immunotherapy. J Immunotherapy. 2007, 30: 131-139. 10.1097/01.cji.0000211327.76266.65.View ArticleGoogle Scholar
- Silva CM: Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene. 2004, 2004 (23): 8017-8023.View ArticleGoogle Scholar
- Rios JL, Reciio MC, Escandell JM, Andujar I: Inhibition of transcription factors by plant-derived compounds and their implications in inflammation and cancer. Curr Pharm Des. 2009, 15: 1212-1237. 10.2174/138161209787846874.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/303/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.